Radiation sensitization with redox modulators: A promising approach

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 2, 2006, Pages 343-354

  Rosenberg, Abby ^a   Knox, Susan ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AQ4N; HIF 1 inhibitor; MGd; Radiation sensitizer; Radiation therapy; Redox modulator; RSR13; Tirapazamine

Indexed keywords

CELLS; DNA; OXYGEN; REDOX REACTIONS; TOXICITY; TUMORS;

AQ4N; HIF-1 INHIBITOR; MGD; RADIATION SENSITIZER; RADIOSENSITIVITY; REDOX MODULATOR; REDOX MODULATORS; RSR13; TIRAPAZAMINE;

RADIOTHERAPY;

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 METHYLOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTIEMETIC AGENT; BANOXANTRONE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DOCETAXEL; EFAPROXIRAL; ETOPOSIDE; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; IBRITUMOMAB TIUXETAN; KETOCONAZOLE; MISONIDAZOLE; PACLITAXEL; PROTEIN INHIBITOR; RADIOSENSITIZING AGENT; RAPAMYCIN; RITUXIMAB; TEMSIROLIMUS; TIRAPAZAMINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WORTMANNIN; YTTRIUM 90;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BACTEREMIA; BRAIN DISEASE; BRAIN INFARCTION; BRAIN METASTASIS; BURNING SENSATION; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIAPHORESIS; DIARRHEA; DIZZINESS; DNA DAMAGE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; FOLLOW UP; GAIT DISORDER; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HEARING LOSS; HEMIPLEGIA; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; KIDNEY DYSFUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN TENSION; PANCREAS CANCER; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RADIATION INJURY; RADIOSENSITIZATION; REVIEW; SCLERA DISEASE; SEIZURE; SEPSIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; UTERINE CERVIX CANCER; VOMITING;

ANILINE COMPOUNDS; ANTHRAQUINONES; CELL HYPOXIA; CLINICAL TRIALS; DNA DAMAGE; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MAXIMUM TOLERATED DOSE; METALLOPORPHYRINS; NEOPLASMS; OXIDATION-REDUCTION; PROPIONIC ACIDS; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 30544446570     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.10.013     Document Type: Review

References (95)

1. R.H. Thomlinson, L.H. Gray The histological structure of some human lung cancers and possible implications for radiotherapy Br J Cancer 9 1955 539 549
2. J.M. Brown Exploiting the hypoxic cancer cell Mechanisms and therapeutic strategies Mol Med Today 6 2000 157 162
3. P.P. Connell, M.K. Martel, S. Hellman Cancer Principles and practice of oncology V.T. De Vita S. Hellman S. Rosenberg Principles of cancer management Radiation therapy 2001 Lippincott, Williams and Wilkins Philadelphia 274 275
4. J.M. Brown Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro7-0582 Radiat Res 64 1975 633 647
5. S. Dische, M.I. Saunders, M.E. Lee Clinical testing of the radiosensitizer Ro 07-0582 Experience with multiple doses Br J Cancer 35 1977 567 579
6. J.M. Brown Clinical trials of radiosensitizers What should we expect? Int J Radiat Oncol Biol Phys 10 1984 425 429
7. J.M. Brown The hypoxic cell A target for selective cancer therapy - Eighteenth Bruce F. Cain memorial award lecture Cancer Res 59 1999 5863 5870
8. Y.M. Delahoussaye, B.G. Wouters, J.E. Evans Intranuclear metabolism of tirapazamine by matrix-associated reductases [Abstract] Proc Am Assoc Cancer Res 38 1997 163
9. J.M. Brown, M.J. Lemmon Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors Cancer Res 50 1990 7745 7749
10. J.F. O'Rourke, G.U. Dachs, J.M. Gleadle Hypoxia response elements Oncol Res 9 1997 327 332
11. S.A. Holden, B.A. Teicher, G. Ara Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma J Natl Cancer Inst 84 1992 187 193
12. M.J. Dorie, J.M. Brown Tumor-specific, schedule-dependent interaction between tirapazamine (SR-4233) and cisplatin Cancer Res 53 1993 4633 4636
13. Z. Goldberg, J. Evans, G. Birrell An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin Int J Radiat Oncol Biol Phys 49 2001 175 182
14. D.R. Gandara, P.N. Lara, Z. Goldberg Tirapazamine Prototype for a novel class of therapeutic agents targeting tumor hypoxia Semin Oncol 29 2002 102 109
15. G.I. Rodriguez, M. Valdivieso, D.D. Von Hoff A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer [Abstract] Prox Am Soc Clin Oncol 15 1996 382a
16. J. Treat, E. Johnson, C. Langer Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer A phase II study J Clin Oncol 16 1998 3524 3527
17. J. Von Pawel, R. Von Roemeling, U. Gatzemeier Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer A report of the international CATAPULT I study group J Clin Oncol 18 2000 1351 1359
18. F. Sheperd, G. Koschel, J. Von Pawel Comparison of tirazone (tirapazamine) and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer: Final results of the international phase III CATAPULT trial. Proceedings of the International Association for the Study of Lung Cancer, 9th World Conference on Lung Cancer, Tokyo, Japan, September 2000 [Abstract] Lung Cancer 28 Suppl 1 2000 28
19. S.K. Williamson, J.J. Crowley, P.N. Lara S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial [Abstract] Proc Am Soc Clin Oncol 22 2003 622
20. L.N. Shulman, L. Buswell, N. Riese Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors Int J Radiat Oncol Biol Phys 44 1999 349 353
21. H.A. Pinto, Q. Le, D. Terris Randomized trial of tirapazamine/cisplatin/ fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced respectable head and neck cancer [Abstract] Pro Am Soc Clin Oncol 21 2002 227a
22. D. Rischen, L. Peters, R. Hicks Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 535 542
23. D. Rischin, L. Peters, R. Fisher Tirapazamine, cisplatin and radiation versus fluorouracil, cisplatin and radiation in patients with locally advanced head and neck cancer A randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02) J Clin Oncol 23 2005 79 87
24. P.S. Craighead, R. Pearcey, G. Stuart A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer Int J Radiat Oncol Biol Phys 48 2000 791 795
25. D.C. Inde, H.I. Pass, E. Glatstein Cancer of the lung V.T. DeVita S. Hellman S.A. Rosenberg Cancer Principles and practices of oncology 1997 Lippincott-Raven Philadelphia 849 949
26. Q.T. Le, J. McCoy, S. Williamson Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004) A Southwest Oncology Group study Clin Cancer Res 10 2004 5418 5424
27. L.H. Patterson, S.M. Raleigh Reductive metabolism Its application to prodrug activation N.J. Gooderham Drug metabolism Towards the next millennium 1998 IOS Press Amsterdam 72 79
28. L.H. Patterson Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents A new class of bioreductive agent Cancer Metastasis Rev 12 1993 119 134
29. L.H. Patterson, S.R. McKeown AQ4N A new approach to hypoxia-activated cancer chemotherapy Br J Cancer 83 2000 1589 1593
30. P.J. Smith, R. Desnoyers, N. Blunt DNA topoisomerase II-dependent cytotoxicity to alkylaminoanthraquinones and their N-oxides Cancer Chemother Pharmacol 39 1997 455 461
31. L.H. Patterson Bioreductively activated antitumor N-oxides The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy Drug Metab Rev 34 2002 581 592
32. S.R. McKeown, O.P. Friery, I.A. McIntyre Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation Br J Cancer Suppl 27 1996 S39 S42
33. M.V. Hejmadi, S.R. McKeown, O.P. Friery DNA damage following combination of radiation with the bioreductive drug AQ4N Possible selective toxicity to oxic and hypoxic cells Br J Cancer 73 1996 499 505
34. S.R. McKeown, M.V. Hejmadi, I.A. McIntyre AQ4N An alkylaminoanthraquinon N-oxide showing bioreductive potential and positive interaction with radiation in vivo Br J Cancer 72 1995 76 81
35. KuDOS Pharmaceutical, Inc. Available at: http://www.kudospharma.co.uk/ r_d/banox.php. Web page title: Banoxantrone. Accessed December 1, 2005.
36. E. Shaw, C. Scott, J. Suh RSR13 plus cranial radiation therapy in patients with brain metastases Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database J Clin Oncol 21 2003 2364 2371
37. J. Whar, M. Gerber, J. Venitz Allosteric modification of oxygen delivery by hemoglobin Anesth Analg 92 2001 615 620
38. D.J. Abraham, F.C. Wireko, R.S. Randad Allosteric modifiers of hemoglobin 2-[4-[[(3,5-disubstituted aniline) carbonyl]-methyl]phenoxyl]-2- methylproprionic acid derivatives that lower the oxygen affinity decreasing agents J Med Chem 34 1991 752 757
39. S. Rockwell, M. Kelley RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy Preliminary studies with EMT6 cells and tumors and normal tissues in mice Radiat Oncol Invest 6 1998 199 208
40. B.A. Teicher, A. Gulshan, Y. Emi RSR13 Effects on tumor oxygenation and response to therapy Drug Dev Res 38 1996 1 11
41. S.R. Khandelwal, P.-S. Lin, C.E. Hall Increased radiation response of FSaII fibrosarcoma in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity Radiat Oncol Invest 4 1996 51059
42. J. Suh, B. Stea, J. Nabid Standard whole brain radiation therapy (WBRT) with supplemental oxygen with or without RSR13 (Efaproxiral) in patients with brain metastases Results of the randomized REACH (RT-009) Study [Abstract] J Clin Oncol 22 2004 1534
43. E. Shaw, C. Scott, B. Stea Survival improvement with RSR13 plus radiation therapy in patients with brain metastases Comparison to the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database 2000 [Abstract 615]. 2000 ASCO Annual Meeting, May 20-23, New Orleans, LA
44. L. Kleinberg, S.A. Grossman, S. Piantadosi Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme J Clin Oncol 17 1999 2593 2603
45. L. Kleinberg, S.A. Grossman, K. Carson Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy Results of a phase II new approaches to brain tumor therapy CNS Consortium Safety and Efficacy Study J Clin Oncol 20 2002 3149 3155
46. S.M. Sagar, M.A. Israel Primary and metastatic tumors of the nervous system D.L. Kasper A.S. Fauci D.L. Longo E. Braunwald S.L. Hauser J.L. Jameson Harrison's principles of internal medicine 2005 McGraw Hill Companies, Inc New York 2453
47. P.Z. New, S. Grossman, T. Mikkelsen Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every 6 weeks in patients with recurrent malignant glioma Results of the phase I NABTT 9806 clinical trial [Abstract] J Clin Oncol 22 2004 1533
48. B. Stea, A. Nabid, J. Kresl Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy [Abstract] J Clin Oncol 22 2004 3090
49. J. Venitz, P.W. Slattum, M. Gerber Pharmacokinetics of escalating IV doses of an allosteric hemoglobin modifier (RSR13) in healthy volunteers [Abstract] Pharm Res 13 1996 s479
50. D. Magda, C. Lepp, G. Nokolay Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species Int J Radiation Oncology Biol Phys 51 2001 1025 1036
51. R. Miller, K. Woodburn, Q. Fan Motexafin gadolinium A redox active drug that enhances the efficacy of bleomycin and doxorubicin Clinical Cancer Research 7 2001 3215 3221
52. R. Miller, K. Woodburn, Q. Fan In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer Int J Radiat Oncol Biol Phys 45 1999 981 989
53. J. Viala, D. Vanel, P. Meingan Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging Preliminary results in brain metastases Radiology 212 1999 755 759
54. Motexafin gadolinium Drugs R & D 5 2004 52 57
55. S. Xu, K. Zakian, H. Thaler Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity Int J Radiat Oncol Biol Phys 49 2001 1381 1390
56. O. Perez, G. Nolan, D. Magda Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells Proc Natl Acad Sci 99 2002 2270 2274
57. J.A. Koutcher, A.A. Alfieri, M.L. Devitt Changes in radiation sensitization induced by Fluosol-DA as measured by 31-P NMR Cancer Res 50 1990 7252 7256
58. E.T. Donnelly, Y. Liu, Y.O. Fatunmbi Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors Int J Radiat Oncol Biol Phys 58 2004 1570 1576
59. K. Woodburn, Y. Luo, Q. Fan In vitro and in vivo enhancement of apoptotic response to radiation and motexafin gadolinium 2001 [Abstract]. 2001 ASCO annual meeting, May 12-15, San Francisco, CA
60. S.W. Young, F. Qing, A. Harriman Gadolinium (III) texaphyrin A tumor selective radiation sensitizer that is detectable by MRI Proc Natl Acad Sci U S A 93 1996 6610 6615
61. E.J. Bernhard, J.B. Mitchel, D. Deen Re-evaluating gadolinium (III) texaphyrin as a radiosensitizing agent Cancer Res 60 2000 86 91
62. S. Rockwell, E. Donnelly, L. Yanfeng Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro Int J Radiat Oncol Biol Phys 54 2002 536 541
63. M. Mehta, P. Rodrigus, C.H.J. Terhaard Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases J Clin Oncol 21 2003 2529 2536
64. C. Meyers, J. Smith, A. Bezjak Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium Results of a randomized phase III trial J Clin Oncol 22 2004 157-156
65. D. Rosenthal, C. Becerra, R. Toto Reversible renal toxicity resulting from high single doses of the new radiosensitizer, gadolinium texaphyrin Am J Clin Oncol (CCT) 23 2000 593 598
66. P. Carde, R. Timmerman, M. Mehta Multicenter phase Ib/II trial of the radiation sensitizer motexafin gadolinium in patients with brain metastases J Clin Oncol 19 2001 2074 2083
67. Pharmacylics. Pharmacyclics announces interim data from phase 1 clinical trial of Xcytrin plus Rituxan and Zevalin for the treatment of B-cell lymphoma. Available at: http://www.pharmacyclics.com/webpage_templates/tert.php3? page_name=pr_1095651527. Accessed November 14, 2005.
68. M. Fakih, R.K. Ramanathan, S. Mani Phase I pharmacokinetic trial of thrice weekly motexafin gadolinium with daily radiation therapy in advanced biliary tree and pancreatic cancers 2001 [Abstract]. 2001 ASCO annual meeting, May 12-15, San Francisco, CA
69. J.M. Ford, W. Seiferheld, M. Mehta Comparison of survival of patients in the phase I study of motexafin gadolinium with radiation therapy for glioblastoma multiforme, with a matched cohort of patients from the RTOG RPA database [Abstract] Proc Am Soc Clin Oncol 22 2003 106
70. J. Suh, E. Chang, R. Timmerman Phase II trial of motefaxin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) 2002 [Abstract]. 2002 ASCO annual meeting, May 18-21, Orlando, FL
71. S. Phan, M. Messina, M. Buffan A phase I trial combining motexafin gadolinium with docetaxel in the treatment of advanced solid tumors 2004 [Abstract]. 2004 ASCO annual meeting, June 5-8, New Orleans, LA
72. A. Giaccia, B.G. Siim, R.S. Johnson HIF-1 as a target for drug development Nat Rev Drug Discovery 2 2003 1 9
73. E.-J. Yeo, Y.-S. Chun, J.-W. Park New anti-cancer strategies targeting HIF-1 Biochem Pharmacol 68 2004 1061 1069
74. L.E. Huang, J. Gu, M. Schau Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2 dependent degradation domain via the ubiquitin-proteasome pathway Proc Natl Acad Sci U S A 95 1998 7987 7992
75. S. Salceda, J. Caro Hypoxia-inducible factor 1 alpha protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes J Biol Chem 272 1997 22642 22647
76. E. Laughner, P. Taghavi, K. Chiles HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha synthesis Novel mechanism for HIF-1 mediated vascular endothelial growth factor expression Mol Cell Biol 21 2001 3995 4004
77. D.A. Chan, P.D. Sutphin, N.D. Denko Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1 alpha J Biol Chem 277 2002 40112 40117
78. X. Sun, J.R. Kanwar, E. Leung Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy Gene Ther 8 2001 638 645
79. Y.S. Chun, E. Choi, T.Y. Kim A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1 alpha gene Biochem J 362 2002 71 79
80. E. Minet, D. Mottet, G. Michel Hypoxia-induced activation of HIF-1 Role of HIF-1 alpha-HSP90 interaction FEBS Lett 460 1999 251 256
81. J.S. Isaacs, Y.J. Jung, E.G. Mimnaugh HSP90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha degradative pathway J Biol Chem 277 2002 29936 29944
82. H. Zhong, K. Chiles, D. Feldser Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells Implications for tumor angiogenesis and therapeutics Cancer Res 60 2000 1541 1545
83. C. Treins, S. Giorgetti-Peraldi, J. Murdaca Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway Biol Chem 277 2002 27975 27981
84. Y.S. Chun, E.J. Yeo, E. Choi Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells Biochem Pharmacol 61 2001 947 954
85. E.J. Eo, Y.S. Chun, Y.S. Cho YC-1 A potential anticancer drug targeting hypoxia-inducible factor 1 J Natl Cancer Inst 95 2003 516 525
86. N.J. Mabjeesh, D.E. Post, M.T. Willard Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells Cancer Res 62 2002 2478 2482
87. R. Fukuda, K. Hirota, F. Fan Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells J Biol Chem 512 2002 157 162
88. D.P. Stiehl, W. Jelkmann, R.H. Wenger Normoxic induction of the hypoxia inducible factor 1 alpha by insulin and interleukin 1 beta involves the phsphatidylinositol 3-kinase pathway FEBS Lett 512 2002 157 162
89. A. Rapisarda, B. Uranchimeg, D.A. Scudiero Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res 62 2002 4316 4324
90. B. Bachtiary, M. Schindl, R. Potter Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radiotherapy for cervical cancer Clin Can Res 9 2003 2234 2240
91. K.J. Williams, B.A. Telfer, D. Xenaki Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor 1 Radiother Oncol 75 2005 89 98
92. B.J. Moeller, Y. Cao, C.Y. Li Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors Role of reoxygenation, free radicals, and stress granules Cancer Cell 5 2004 429 441
93. B.J. Moeller, M.R. Dreher, Z.N. Rabbani Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity Cancer Cell 8 2005 99 110
94. X. Li, R. Luwor, Y. Lu Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C335 by perifosine in PTEN-deficient cancer cells Oncogene 2005 Sep 19; [Epub ahead of print]
95. M. Rooseboom, J.N. Commandeur, N.P. Vermeulen Enzyme-catalyzed activation of anticancer prodrugs Pharmacol Rev 56 2004 53 102